THE 2-MINUTE RULE FOR MBL77

For patients with symptomatic condition demanding therapy, ibrutinib is usually recommended according to 4 period III randomized clinical trials evaluating ibrutinib with chlorambucil monotherapy106 and also other typically utilized CIT combos, namely FCR, bendamustine plus rituximab and chlorambucil furthermore obinutuzumab (ClbO).107–109 Ibruti